Phaseline

Targets › FUSE

FUSE: drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 3; Infectious disease.

Open in Phaseline: the race on FUSE, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Baxis PharmaceuticalsFusidic Acid 1%
Bacterial protein synthesis inhibitor targeting elongation factor G
FUSEPhase 3Bacterial Conjunctivitis–

Conditions

Bacterial Conjunctivitis (1)

Modalities

small molecule (1)

Companies

Baxis Pharmaceuticals (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.